Hawthorn executes deal with university
MADISON — Hawthorn Pharmaceuticals Inc. has struck a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer.
Under the terms of the agreement, Madison-based Hawthorn will receive an exclusive worldwide license to develop and commercialize the antibody portfolio.
“We are excited to be working with the world=-class cancer scientists at University of Pittsburgh’s Cancer Institute who have devoted their entire careers to improving people’s lives through cancer discovery,” said Rob Lewis, chief scientific officer at Hawthorn.
“There are many strengths created by our relationship with the University of Pittsburgh that promotes the rapid development of these novel antibodies,” said Max Draughn, president and CEO of Hawthorn. “Our collaboration is a shared vision to ultimately extend and improve the lives of many children and adults who suffer with various cancers.”
To sign up for Mississippi Business Daily Updates, click here.
FOLLOW THE MBJ ON TWITTERMy Tweets
Top Posts & Pages
- DAVID DALLAS: You say “Obama”, I say “Ebola”
- Pickering lists concerns over Mississippi Adequate Education Program formula
- Peavey's wellness program honored after workers drop 1,000 pounds
- Group, lesbian couples look to overturn state's ban on same-sex marriages
- Judge gets more time to fight efforts to remove him from office
- Voters to decide whether hunting, fishing is constitutional right
- State renews battle over water use with city of Memphis
- Coast cleanup nets 1,600 bags of trash — and a watermelon patch
- State's bad bridges continue to raise concerns among officials